NO325501B1 - Piperazinforbindelser, anvendelse og fremstilling derav, samt farmasoytisk preparat. - Google Patents

Piperazinforbindelser, anvendelse og fremstilling derav, samt farmasoytisk preparat. Download PDF

Info

Publication number: NO325501B1
Authority: NO; Norway
Prior art keywords: compound; pharmaceutical preparation; patient; treatment; disorders
Prior art date: 2000-11-28

Application number

NO20032390A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032390D0 (no

NO20032390L (no

Inventor

Michael Gerard Kelly

Wayne Everett Childers

Sharon Joy Rosenzweig-Lipson

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-28

Filing date

2003-05-27

Publication date

2008-05-26

2003-05-27 Application filed by Wyeth Corp filed Critical Wyeth Corp

2003-05-27 Publication of NO20032390D0 publication Critical patent/NO20032390D0/no

2003-07-22 Publication of NO20032390L publication Critical patent/NO20032390L/no

2008-05-26 Publication of NO325501B1 publication Critical patent/NO325501B1/no

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 24
238000002360 preparation method Methods 0.000 title description 9
150000004885 piperazines Chemical class 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 85
150000003839 salts Chemical class 0.000 claims description 18
238000004519 manufacturing process Methods 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 13
238000000034 method Methods 0.000 claims description 11
208000010877 cognitive disease Diseases 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
208000035475 disorder Diseases 0.000 claims description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
-1 piperazine compound Chemical class 0.000 claims description 7
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
208000006011 Stroke Diseases 0.000 claims description 6
206010003805 Autism Diseases 0.000 claims description 5
208000020706 Autistic disease Diseases 0.000 claims description 5
208000018737 Parkinson disease Diseases 0.000 claims description 5
230000010933 acylation Effects 0.000 claims description 5
238000005917 acylation reaction Methods 0.000 claims description 5
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 4
208000019901 Anxiety disease Diseases 0.000 claims description 4
208000030814 Eating disease Diseases 0.000 claims description 4
208000017701 Endocrine disease Diseases 0.000 claims description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
208000019695 Migraine disease Diseases 0.000 claims description 4
208000019430 Motor disease Diseases 0.000 claims description 4
201000001880 Sexual dysfunction Diseases 0.000 claims description 4
208000000323 Tourette Syndrome Diseases 0.000 claims description 4
208000016620 Tourette disease Diseases 0.000 claims description 4
206010046543 Urinary incontinence Diseases 0.000 claims description 4
239000000654 additive Substances 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
235000014632 disordered eating Nutrition 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
206010027599 migraine Diseases 0.000 claims description 4
229960002715 nicotine Drugs 0.000 claims description 4
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 4
201000000980 schizophrenia Diseases 0.000 claims description 4
231100000872 sexual dysfunction Toxicity 0.000 claims description 4
208000019116 sleep disease Diseases 0.000 claims description 4
NRPQELCNMADTOZ-OAQYLSRUSA-N 4-cyano-n-[(2r)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide Chemical compound C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)N(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-OAQYLSRUSA-N 0.000 claims description 3
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 3
230000000996 additive effect Effects 0.000 claims description 3
230000029936 alkylation Effects 0.000 claims description 3
238000005804 alkylation reaction Methods 0.000 claims description 3
208000015114 central nervous system disease Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
208000013403 hyperactivity Diseases 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
GXYZREDEYDFJPT-ZMBIFBSDSA-N 4-cyano-n-[(2r)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide;hydrochloride Chemical compound Cl.C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)N(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 GXYZREDEYDFJPT-ZMBIFBSDSA-N 0.000 claims description 2
206010041250 Social phobia Diseases 0.000 claims description 2
239000002168 alkylating agent Substances 0.000 claims description 2
229940100198 alkylating agent Drugs 0.000 claims description 2
150000001408 amides Chemical class 0.000 claims description 2
150000007514 bases Chemical class 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
238000003776 cleavage reaction Methods 0.000 claims description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 2
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 2
150000004820 halides Chemical class 0.000 claims description 2
206010027175 memory impairment Diseases 0.000 claims description 2
230000007017 scission Effects 0.000 claims description 2
230000001331 thermoregulatory effect Effects 0.000 claims description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
NRPQELCNMADTOZ-UHFFFAOYSA-N 4-cyano-n-[2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide Chemical compound C1CN(C=2C=3OCCOC=3C=CC=2)CCN1C(C)CN(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-UHFFFAOYSA-N 0.000 claims 1
208000000044 Amnesia Diseases 0.000 claims 1
208000026139 Memory disease Diseases 0.000 claims 1
230000002152 alkylating effect Effects 0.000 claims 1
230000006984 memory degeneration Effects 0.000 claims 1
208000023060 memory loss Diseases 0.000 claims 1
239000008177 pharmaceutical agent Substances 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 description 16
230000000694 effects Effects 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
239000000556 agonist Substances 0.000 description 9
239000007788 liquid Substances 0.000 description 9
230000004044 response Effects 0.000 description 9
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 8
239000005557 antagonist Substances 0.000 description 8
125000003118 aryl group Chemical group 0.000 description 8
238000012360 testing method Methods 0.000 description 8
125000000753 cycloalkyl group Chemical group 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
239000000969 carrier Substances 0.000 description 5
125000001072 heteroaryl group Chemical group 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000000470 constituent Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 2
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
229940126062 Compound A Drugs 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical group NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
230000005714 functional activity Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
208000027061 mild cognitive impairment Diseases 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical group COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000011688 Generalised anxiety disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033664 Panic attack Diseases 0.000 description 1
206010033864 Paranoia Diseases 0.000 description 1
208000027099 Paranoid disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000006399 behavior Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000028683 bipolar I disease Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001722 carbon compounds Chemical class 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000013461 design Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000945 filler Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
150000002222 fluorine compounds Chemical class 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
208000029364 generalized anxiety disease Diseases 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000007928 imidazolide derivatives Chemical class 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004558 lewy body Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
WGNFRNVIFIRYDD-MRXNPFEDSA-N n-[(2r)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]pyridin-2-amine Chemical compound C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)NC1=CC=CC=N1 WGNFRNVIFIRYDD-MRXNPFEDSA-N 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000031868 operant conditioning Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000012057 packaged powder Substances 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
229940055726 pantothenic acid Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000003727 serotonin 1A antagonist Substances 0.000 description 1
239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Endocrinology (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20032390A 2000-11-28 2003-05-27 Piperazinforbindelser, anvendelse og fremstilling derav, samt farmasoytisk preparat. NO325501B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25330100P	2000-11-28	2000-11-28
US29781401P	2001-06-13	2001-06-13
PCT/US2001/043160 WO2002044142A2 (en)	2000-11-28	2001-11-27	Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders

Publications (3)

Publication Number	Publication Date
NO20032390D0 NO20032390D0 (no)	2003-05-27
NO20032390L NO20032390L (no)	2003-07-22
NO325501B1 true NO325501B1 (no)	2008-05-26

Family

ID=26943115

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032390A NO325501B1 (no)	2000-11-28	2003-05-27	Piperazinforbindelser, anvendelse og fremstilling derav, samt farmasoytisk preparat.

Country Status (25)

Country	Link
US (3)	US6469007B2 (es)
EP (1)	EP1339406B1 (es)
JP (1)	JP4198989B2 (es)
KR (1)	KR100835552B1 (es)
CN (1)	CN100352437C (es)
AR (1)	AR035603A1 (es)
AT (1)	ATE269078T1 (es)
AU (2)	AU3765402A (es)
BR (1)	BR0115609A (es)
CA (1)	CA2428039C (es)
DE (1)	DE60103927T2 (es)
DK (1)	DK1339406T3 (es)
EA (1)	EA005925B1 (es)
ES (1)	ES2222401T3 (es)
HK (1)	HK1057864A1 (es)
HU (1)	HUP0400551A2 (es)
IL (1)	IL156098A0 (es)
MX (1)	MXPA03004677A (es)
NO (1)	NO325501B1 (es)
NZ (1)	NZ526150A (es)
PL (1)	PL363219A1 (es)
PT (1)	PT1339406E (es)
TR (1)	TR200401546T4 (es)
TW (1)	TWI224102B (es)
WO (1)	WO2002044142A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6432826B1 (en) *	1999-11-29	2002-08-13	Applied Materials, Inc.	Planarized Cu cleaning for reduced defects
US20060287335A1 (en) *	2000-11-28	2006-12-21	Wyeth	Serotonergic agents for treating sexual dysfunction
US20060223824A1 (en) *	2000-11-28	2006-10-05	Wyeth	Serotonergic agents
EP1408976B3 (en)	2001-07-20	2010-08-25	Psychogenics Inc.	Treatment for attention-deficit hyperactivity disorder
CA2477906A1 (en)	2002-03-12	2003-09-25	Ivo Jirkovsky	Process for making chiral 1,4-disubstituted piperazines
US7361773B2 (en)	2002-03-12	2008-04-22	Wyeth	Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
US7091349B2 (en)	2002-03-12	2006-08-15	Wyeth	Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
EP1483255B1 (en)	2002-03-12	2009-08-12	Wyeth	Process for synthesizing chiral n-aryl piperazines
GB0219961D0 (en) *	2002-08-28	2002-10-02	Pfizer Ltd	Oxytocin inhibitors
US20040192730A1 (en) *	2003-03-13	2004-09-30	Dynogen Pharmaceuticals, Inc.	Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
US20050215561A1 (en) *	2004-03-19	2005-09-29	Krishnendu Ghosh	Pharmaceutical dosage forms and compositions
US20050209245A1 (en) *	2004-03-19	2005-09-22	Wyeth	Process for preparing N-aryl-piperazine derivatives
US20070099931A1 (en) *	2004-03-19	2007-05-03	Wyeth	Pharmaceutical dosage forms and compositions
KR100646337B1 (ko) *	2004-06-30	2006-11-23	주식회사 롯데기공	보일러의 누수 감지방법
ES2346771T3 (es) *	2004-10-15	2010-10-20	The Government Of The Usa As Represented By The Secretary Of The Department Of Health And Human Serv	Peptidos con multiples dominios a-helicoidales anfipaticos y procedimientos para su uso.
JP2008531694A (ja) *	2005-03-01	2008-08-14	ワイス	結晶性および非晶性４−シアノ−ｎ−｛（２ｒ）−２−［４−（２，３−ジヒドロ−ベンゾ［１，４］ジオキシン−５−イル）−ピペラジン−１−イル］−プロピル｝−ｎ−ピリジン−２−イル−ベンズアミド塩酸塩
TW200800959A (en) *	2005-06-10	2008-01-01	Wyeth Corp	Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
EP1893617A1 (en) *	2005-06-17	2008-03-05	Wyeth a Corporation of the State of Delaware	Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
WO2007089616A2 (en) *	2006-01-26	2007-08-09	The University Of Rochester	Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier
TW200808741A (en) *	2006-06-09	2008-02-16	Wyeth Corp	6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) *	2006-06-09	2008-03-01	Wyeth Corp	Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) *	2006-06-09	2008-02-16	Wyeth Corp	Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
US20080262228A1 (en) *	2006-11-28	2008-10-23	Wyeth	Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof
CL2008000119A1 (es)	2007-01-16	2008-05-16	Wyeth Corp	Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
WO2009129263A1 (en) *	2008-04-15	2009-10-22	The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv.	Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX9201991A (es)	1991-05-02	1992-11-01	Jonh Wyeth & Brother Limited	Derivados de piperazina y procedimiento para su preparacion.
GB9514901D0 (en)	1995-07-20	1995-09-20	American Home Prod	Piperazine derivatives

2001
- 2001-11-13 US US10/010,575 patent/US6469007B2/en not_active Expired - Fee Related
- 2001-11-27 DE DE60103927T patent/DE60103927T2/de not_active Expired - Lifetime
- 2001-11-27 TW TW090129285A patent/TWI224102B/zh not_active IP Right Cessation
- 2001-11-27 CN CNB018196853A patent/CN100352437C/zh not_active Expired - Fee Related
- 2001-11-27 ES ES01986458T patent/ES2222401T3/es not_active Expired - Lifetime
- 2001-11-27 WO PCT/US2001/043160 patent/WO2002044142A2/en active IP Right Grant
- 2001-11-27 MX MXPA03004677A patent/MXPA03004677A/es active IP Right Grant
- 2001-11-27 AT AT01986458T patent/ATE269078T1/de not_active IP Right Cessation
- 2001-11-27 KR KR1020037007064A patent/KR100835552B1/ko not_active IP Right Cessation
- 2001-11-27 PT PT01986458T patent/PT1339406E/pt unknown
- 2001-11-27 DK DK01986458T patent/DK1339406T3/da active
- 2001-11-27 AR ARP010105502A patent/AR035603A1/es not_active Application Discontinuation
- 2001-11-27 PL PL01363219A patent/PL363219A1/xx not_active Application Discontinuation
- 2001-11-27 BR BR0115609-8A patent/BR0115609A/pt not_active Application Discontinuation
- 2001-11-27 AU AU3765402A patent/AU3765402A/xx active Pending
- 2001-11-27 HU HU0400551A patent/HUP0400551A2/hu unknown
- 2001-11-27 NZ NZ526150A patent/NZ526150A/en unknown
- 2001-11-27 IL IL15609801A patent/IL156098A0/xx unknown
- 2001-11-27 EP EP01986458A patent/EP1339406B1/en not_active Expired - Lifetime
- 2001-11-27 EA EA200300619A patent/EA005925B1/ru not_active IP Right Cessation
- 2001-11-27 TR TR2004/01546T patent/TR200401546T4/xx unknown
- 2001-11-27 JP JP2002546512A patent/JP4198989B2/ja not_active Expired - Fee Related
- 2001-11-27 AU AU2002237654A patent/AU2002237654B2/en not_active Ceased
- 2001-11-27 CA CA2428039A patent/CA2428039C/en not_active Expired - Fee Related
2002
- 2002-08-14 US US10/218,251 patent/US6586436B2/en not_active Expired - Fee Related
2003
- 2003-05-20 US US10/441,536 patent/US7026320B2/en not_active Expired - Fee Related
- 2003-05-27 NO NO20032390A patent/NO325501B1/no not_active IP Right Cessation
2004
- 2004-02-04 HK HK04100730A patent/HK1057864A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP1339406B1 (en)	2004-06-16
HUP0400551A2 (en)	2006-02-28
WO2002044142A2 (en)	2002-06-06
WO2002044142A3 (en)	2002-08-08
TWI224102B (en)	2004-11-21
CA2428039A1 (en)	2002-06-06
US6586436B2 (en)	2003-07-01
CN100352437C (zh)	2007-12-05
NO20032390D0 (no)	2003-05-27
EA005925B1 (ru)	2005-08-25
JP4198989B2 (ja)	2008-12-17
CA2428039C (en)	2011-08-09
PL363219A1 (en)	2004-11-15
MXPA03004677A (es)	2003-09-05
ATE269078T1 (de)	2004-07-15
AU2002237654B2 (en)	2005-07-28
ES2222401T3 (es)	2005-02-01
DK1339406T3 (da)	2004-09-27
AR035603A1 (es)	2004-06-16
EA200300619A1 (ru)	2003-10-30
DE60103927D1 (de)	2004-07-22
DE60103927T2 (de)	2005-06-23
CN1477961A (zh)	2004-02-25
AU3765402A (en)	2002-06-11
US7026320B2 (en)	2006-04-11
PT1339406E (pt)	2004-10-29
US6469007B2 (en)	2002-10-22
IL156098A0 (en)	2003-12-23
KR20030051879A (ko)	2003-06-25
JP2004520289A (ja)	2004-07-08
NZ526150A (en)	2004-11-26
NO20032390L (no)	2003-07-22
EP1339406A2 (en)	2003-09-03
US20030216408A1 (en)	2003-11-20
BR0115609A (pt)	2003-11-11
US20020107254A1 (en)	2002-08-08
US20030022901A1 (en)	2003-01-30
TR200401546T4 (tr)	2004-09-21
HK1057864A1 (en)	2004-04-23
KR100835552B1 (ko)	2008-06-09

Publication	Publication Date	Title
NO325501B1 (no)	2008-05-26	Piperazinforbindelser, anvendelse og fremstilling derav, samt farmasoytisk preparat.
AU2002237654A1 (en)	2002-08-15	Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
US5696137A (en)	1997-12-09	Azaheterocyclymethyl-chromans
US20020173512A1 (en)	2002-11-21	Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use
MX2011012712A (es)	2012-01-30	Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
NO329319B1 (no)	2010-09-27	Kinolinforbindelser, fremgangsmåter for fremstilling derav, farmsøytiske preparater samt anvendelser av forbindelsene
SK188399A3 (en)	2000-07-11	Substituted 1,2,3,4-tetrahydronaphthalene derivatives
CZ350796A3 (en)	1997-06-11	Piperazine derivatives as 5ht1a antagonists
KR20010024077A (ko)	2001-03-26	치환된 크로만 유도체
JP4880583B2 (ja)	2012-02-22	新規なベンジル（ベンジリデン）−ラクタム誘導体
AU2003243089A1 (en)	2004-01-06	Novel compounds, their use and preparation
CZ281714B6 (cs)	1996-12-11	Piperidylmethylsubstituované deriváty chromanu
WO2000049017A1 (en)	2000-08-24	1-((indoly azacycloalkyl) alkyl)-2,1, 3-benzothiadiazole 2,2-dioxides exhibiting 5-ht2a receptor activity
SK10222001A3 (sk)	2002-03-05	Morfolinobenzamidové soli
US7816362B2 (en)	2010-10-19	Serotonergic agents
MXPA05002740A (es)	2005-06-03	Derivados de cicloalquilamina antidepresivos de 2,3-dihidro+1,4-benzodioxan.
ZA200304994B (en)	2004-10-04	Piperazine derivatives, their preparation and their use for treating central nervous systems (CNS) disorders.
JP2010534705A (ja)	2010-11-11	Ｈ１受容体のアンタゴニストとして有用なスピロ化合物
EA002979B1 (ru)	2002-12-26	Спироимидазолиновые соединения, способ их получения и фармацевтическая композиция, содержащая их
MXPA97000418A (es)	1998-10-15	(1h-indol-4-il)-piperidina o tetrahidropiridina etilaminas etilcarboxamidas
MXPA00010456A (es)	2001-07-31	Agentes serotonergicos
MXPA06010630A (es)	2007-04-20	Nuevos derivados de bencil(ideno)-lactamas

Legal Events

Date	Code	Title	Description
2010-06-28	MM1K	Lapsed by not paying the annual fees